Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.
In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"
There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.
The FDA has cleared Curis to resume enrollment of patients in their Take Aim Leukemia study.
ABL602 is a bispecific antibody in early development that targets CLL-1, a molecule found in leukemia stem cells but is absent in normal stem cells.
CAR-T therapy targeting CD70 combined with azacitidine is development and so far has shown early promising results.
Dr. Ravandi, an AML expert from MD Anderson discusses his trial evaluating the use of an oral form of decitabine in combination with venetoclax.
Dr. Stein discusses his two posters at the EHA annual congress evaluating tamibarotene and lanraplenib (LANRA), two new drugs in development for AML.
Dr. David Sallman speaks to us at the 2022 EHA meeting about his trial of magrolimab and azacitidine in high-risk MDS, a condition that can transform into AML.
Dr. Harry Erba provides an update on his clinical trial evaluating the use of a new FLT3 inhibitor called quizartinib at the annual EHA Congress.
This update provides the first clear signal that MRD responses following DCP-001 vaccination translate into relevant survival benefits for AML patients.
Clinical trial results are in for new drug that provides a treatment option for adult patients that can potentially reduce the number of doctor office visits.